Linked Life Data

17033717

Source:http://linkedlifedata.com/resource/pubmed/id/17033717

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17033717rdf:typepubmed:Citationlld:pubmed
pubmed-article:17033717lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:17033717lifeskim:mentionsumls-concept:C1518174lld:lifeskim
pubmed-article:17033717lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:17033717lifeskim:mentionsumls-concept:C1099354lld:lifeskim
pubmed-article:17033717lifeskim:mentionsumls-concept:C0312418lld:lifeskim
pubmed-article:17033717lifeskim:mentionsumls-concept:C1332397lld:lifeskim
pubmed-article:17033717lifeskim:mentionsumls-concept:C0036667lld:lifeskim
pubmed-article:17033717lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:17033717pubmed:issue10lld:pubmed
pubmed-article:17033717pubmed:dateCreated2006-10-11lld:pubmed
pubmed-article:17033717pubmed:abstractTextChanges in drug sensitivity in Bcl-XL small interfering RNA (siRNA) transfected Hepg2 hepatocellular carcinoma cells were investigated in this study. Bcl-XL siRNA and negative siRNA expression vector were constructed and stably transfected into Hepg2 cells. Reverse transcription (RT)-PCR, western blot and immunofluorescence were used to detect the target gene expression at mRNA and protein levels. Drug sensitivity of the cells to 5-fluorouracil (5-FU) and hydroxycamptothecin (HCPT) were evaluated with MTT. The Bcl-XL mRNA and protein expression levels in Bcl-XL siRNA transfectants were reduced compared with negative siRNA transfectants or mock cells. MTT results showed that Bcl-XL siRNA transfected cells have a higher cell inhibition rate than negative vector transfected cells or untreated cells after treatment with 13, 130, 1300 and 13,000 mg/L of 5-FU. Bcl-XL siRNA transfected cells also showed increased drug-sensitivity compared with negative vector transfected cells or untreated cells after treatment with 0.18, 0.36, 0.72 and 1.44 mg/L HCPT. Flow cytometry (FCM) results demonstrated that the sub-G1 population increased in the Bcl-XL siRNA group, compared with the negative siRNA group and untreated control group, after the addition of 5-FU (1300 mg/L) and HCPT (0.72 mg/L). siRNA targeting Bcl-XL gene can specifically down-regulate Bcl-XL expression in Hepg2 cells, and can increase spontaneous cell apoptosis and sensitize cells to 5-FU or HCPT.lld:pubmed
pubmed-article:17033717pubmed:languageenglld:pubmed
pubmed-article:17033717pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17033717pubmed:citationSubsetIMlld:pubmed
pubmed-article:17033717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17033717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17033717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17033717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17033717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17033717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17033717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17033717pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17033717pubmed:statusMEDLINElld:pubmed
pubmed-article:17033717pubmed:monthOctlld:pubmed
pubmed-article:17033717pubmed:issn1672-9145lld:pubmed
pubmed-article:17033717pubmed:authorpubmed-author:ZhongMiaoMlld:pubmed
pubmed-article:17033717pubmed:authorpubmed-author:LiaoDuan-Fang...lld:pubmed
pubmed-article:17033717pubmed:authorpubmed-author:LeiXiao-YongX...lld:pubmed
pubmed-article:17033717pubmed:authorpubmed-author:ZhuBing-YangB...lld:pubmed
pubmed-article:17033717pubmed:authorpubmed-author:FengLan-FangL...lld:pubmed
pubmed-article:17033717pubmed:authorpubmed-author:TangSheng-Son...lld:pubmed
pubmed-article:17033717pubmed:issnTypePrintlld:pubmed
pubmed-article:17033717pubmed:volume38lld:pubmed
pubmed-article:17033717pubmed:ownerNLMlld:pubmed
pubmed-article:17033717pubmed:authorsCompleteYlld:pubmed
pubmed-article:17033717pubmed:pagination704-10lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:meshHeadingpubmed-meshheading:17033717...lld:pubmed
pubmed-article:17033717pubmed:year2006lld:pubmed
pubmed-article:17033717pubmed:articleTitleBcl-XL small interfering RNA enhances sensitivity of Hepg2 hepatocellular carcinoma cells to 5-fluorouracil and hydroxycamptothecin.lld:pubmed
pubmed-article:17033717pubmed:affiliationInstitute of Pharmacy and Pharmacology, Nanhua University, Hengyang 421001, China. lei_xiaoyong@yahoo.com.cnlld:pubmed
pubmed-article:17033717pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17033717pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17033717lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17033717lld:pubmed